AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 10, 2024
Scientists have identified a key protein in the development of Alzheimer’s disease which could prove critical in slowing or even halting the condition’s progress.
pharmaphorum
MARCH 10, 2024
The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of the drug. Lilly said the US regulator “wants to further understand topics related to evaluating the safety and efficacy of donanemab,” which includes the safety and efficacy results of its pivotal TRAILBLAZER-ALZ 2 study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 10, 2024
In a remarkable display of scientific prowess and commitment to public health, the Indian Council of Medical Research (ICMR) has spearheaded a series of ground-breaking initiatives aimed at tackling infectious diseases and bolstering diagnostic capabilities nationwide, according to its Annual Report 2023.
JAMA Internal Medicine
MARCH 10, 2024
This review provides guidance on the treatment of obesity in adults, including lifestyle interventions, antiobesity medications, and surgical approaches.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Law Blog
MARCH 10, 2024
Last August the Food and Drug Administration (“FDA”)/Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule cannabis from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By doing so, FDA/HHS believe that cannabis no longer meets schedule I criteria but does not meet schedule II criteria either.
JAMA Internal Medicine
MARCH 10, 2024
This JAMA Internal Medicine Patient Page describes how to use injectable weight-loss medications as well as their risks and benefits.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
JAMA Internal Medicine
MARCH 10, 2024
This randomized clinical trial evaluates a computerized clinical decision support system for the management of uncontrolled hypertension in patients with chronic kidney disease.
Drug Patent Watch
MARCH 10, 2024
SINUVA (mometasone furoate) Intersect ent inc Patent: 7,951,131 Expiration: Mar 12, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of March 10, 2024 appeared first on DrugPatentWatch - Make Better Decisions.
Trialfacts
MARCH 10, 2024
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Study Location Research Center: The University of Texas Southwestern Medical Center Location: 1440 Empire Central Drive, Ste LD4.100, Dallas, TX 75247 Lead Researchers: Sherwood Brown, MD, PhD, MBA and Marlene Freeman, MD IRB: This study has been reviewed and approved by the UT Southwestern Medical Center Institutional Review Board About the Study A number of women grapple with
Expert insights. Personalized for you.
231 
Let's personalize your content